ArticleJournal of translational medicine2022

RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.

Chunyue Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.